OptimizeRx Corporation Announces CEO Transition and Interim Appointment

OptimizeRx Corporation, listed on the Nasdaq under the symbol OPRX, recently disclosed in an 8-K filing to the Securities and Exchange Commission that their Chief Executive Officer (CEO) and Board Member, William J. Febbo, will be stepping down from his roles, effective December 31, 2024. This move is to enable him to pursue other opportunities. […]

Leave a Reply

Your email address will not be published.

Previous post Elevai Labs (NASDAQ: ELAB) Dismisses TPS Thayer, LLC as Independent Registered Public Accounting Firm
Next post RAPT Therapeutics Announces License Agreement and Private Placement